Please assess the completion status of the following clinical trial:

Trial Title: Effects of Atorvastatin on Myonecrosis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Patients must be aged 18 or over.~* Patients must provide written informed consent.~* Patients are presenting with unstable angina (defined as new onset chest pain, accelerating chest pain, chest pain at rest and ST-segment depression on the electrocardiogram \[EKG\])~* Patients undergoing successful coronary stent implantation of the (presumed) culprit lesion (defined as \< 50% residual stenosis).~Exclusion Criteria:~* Any patient who is unable to give written informed consent.~* Any condition which, in the investigator's opinion, would interfere with optimal participation in the study or produce a significant risk to the patient.~* Patients presenting with an ST-elevation myocardial infarction (MI).~* Patients with elevated troponin, CK, or CK-MB (above the upper limit of normal).~* Patients already on high-dose statin therapy (defined as any statin equivalent to atorvastatin ≥ 40 mg).~* Patients who took any statin agent within 24 hours of presentation to the cardiac catheterization laboratory.~* Patients with active hepatic disease or myositis, in whom statin therapy is contraindicated.~* Patients with hypersensitivity to atorvastatin.~* Patients with procedural complications, including unsuccessful percutaneous transluminal coronary angioplasty (PTCA)/stenting, major side-branch occlusion, flow-limiting dissections at the completion of the procedure, emergent coronary artery bypass surgery, peri-procedural thrombus formation with distal embolization, stent thrombosis within the first 24 hours, repeat emergent PCI within 24 hours, and death within 24 hours.~* Cardiogenic shock.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- atorvastatin 80 mg (Type: ACTIVE_COMPARATOR): 80 mg atorvastatin on average of 2-4 hours pre angio/PCI for ACS
- placebo oral tablet (Type: PLACEBO_COMPARATOR): placebo on average of 2-4 hours pre angio/PCI for ACS
- Screening (Type: NO_INTERVENTION): Patients signed consent if willing to participate. Patients will continue onto randomization if appropriate per inc/exc (i.e. stent placement) otherwise screen fail

Based on this trial design, predict the completion outcome and termination type (if applicable).